Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a report released on Wednesday, Marketbeat reports. They presently have a $11.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 378.26% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Stock Up 1.3 %

Shares of NYSE CATX opened at $2.30 on Wednesday. Perspective Therapeutics has a twelve month low of $2.22 and a twelve month high of $19.05. The stock has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $6.51.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares during the last quarter. State Street Corp lifted its stake in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after purchasing an additional 355,685 shares during the last quarter. FMR LLC boosted its holdings in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after purchasing an additional 44,174 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.